Foamix, a specialty pharmaceutical company, and LEO Pharma have entered into a settlement and license agreement with an affiliate of Teva to resolve pending patent litigation involving Finacea Foam.

(RTTNews) - Foamix Pharmaceuticals Ltd. (FOMX) said Tuesday that, together with LEO Pharma, it has settled the Hatch-Waxman litigation with Perrigo, relating to Finacea Foam. Terms of the settlement ...

Bayer HealthCare announced that the Food and Drug Administration (FDA) has approved Finacea (azelaic acid) Foam 15% for the topical treatment of inflammatory papules and pustules of mild to moderate ...

(RTTNews) - Perrigo Co. plc (PRGO) said Tuesday that it has settled its Hatch-Waxman litigation relating to its tentatively-approved generic version of Finacea Foam (azelaic acid) 15% pursued by LEO ...

DUBLIN, Feb. 20, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has filed a Paragraph IV Abbreviated New Drug Application with the U.S. Food and Drug ...

Oil prices edged lower on Friday after big falls in the last session over concerns about possible softening of U.S. demand and broad oversupply that offset worry about supply disruption from conflict ...

HealthDay News — The FDA has approved a new prescription treatment for rosacea. Finacea (azelaic acid) Foam, 15%, has been approved for the topical treatment of mild to moderate rosacea, according to ...

Bayer HealthCare announced the launch of Finacea Foam (azelaic acid) 15% for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. Finacea Foam was approved by ...

The first commercial product developed for the American market by Israeli biotech start-up Foamix has received FDA approval, the company announced last week. Finacea Foam, a 15% solution of azelaic ...